Public Profile

Camurus

Camurus AB, a pioneering biopharmaceutical company headquartered in Sweden, focuses on developing innovative medicines for patients with severe and chronic conditions. Founded in 2016, Camurus has rapidly established itself in the pharmaceutical industry, particularly in the fields of pain management and addiction treatment. The company is renowned for its proprietary FluidCrystal® technology, which enables the formulation of long-acting injectable therapies. This unique approach enhances patient compliance and treatment outcomes. Camurus has achieved significant milestones, including the successful launch of its lead product, Buvidal®, for opioid dependence, positioning itself as a leader in the market. With a strong presence in Europe and expanding operations globally, Camurus continues to make strides in improving patient care through its advanced therapeutic solutions.

DitchCarbon Score

How does Camurus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

31

Industry Average

Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

5

Industry Benchmark

Camurus's score of 31 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.

63%

Camurus's reported carbon emissions

In 2023, Camurus reported total carbon emissions of approximately 561,800 kg CO2e. This figure includes 158,900 kg CO2e from Scope 1 emissions, primarily from mobile combustion, and 11,680 kg CO2e from Scope 2 emissions. The company also recorded significant Scope 3 emissions, totalling about 385,600 kg CO2e, with the largest contributions from downstream transportation and distribution (approximately 287,714 kg CO2e) and purchased goods and services (about 50,700 kg CO2e). In 2022, Camurus's total emissions were approximately 231,600 kg CO2e, with Scope 1 emissions at 162,400 kg CO2e and Scope 2 emissions at 16,690 kg CO2e. The Scope 3 emissions for that year were around 60,300 kg CO2e. Despite these figures, Camurus has not publicly disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction strategies suggests a need for further transparency in their climate action plans.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
162,400
000,000
Scope 2
8,990
00,000
Scope 3
60,300
000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Camurus's primary industry is Medical, precision and optical instruments, watches and clocks (33), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Camurus is headquartered in SE, which has a rank of very low, indicating very low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Camurus is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Jazz Pharmaceuticals (EUSA Pharma USA) Inc.

US
Health and social work services (85)
Updated 16 days ago
DitchCarbon Score

Td Medtekhnologii, Ooo

RU
Food products nec
Updated 13 days ago

Abeona Therapeutics Inc.

US
Health and social work services (85)
Updated 13 days ago

Fortovia Therapeutics, Inc.

US
Health and social work services (85)
Updated 16 days ago
DitchCarbon Score

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers